IRAK2 has a critical role in promoting feed-forward amplification of epidermal inflammatory responses.

[1]  James T. Elder,et al.  Atopic Dermatitis Is an IL-13-Dominant Disease with Greater Molecular Heterogeneity Compared to Psoriasis. , 2019, The Journal of investigative dermatology.

[2]  A. Waisman,et al.  Imiquimod-Induced Psoriasis in Mice Depends on the IL-17 Signaling of Keratinocytes. , 2019, The Journal of investigative dermatology.

[3]  T. Nomura,et al.  The epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis , 2018, Nature Immunology.

[4]  James T. Elder,et al.  Meta-analysis of RNA sequencing datasets reveals an association between TRAJ23, psoriasis, and IL-17A. , 2018, JCI insight.

[5]  Junjiu Huang,et al.  Gain‐of‐Function Mutation of Card14 Leads to Spontaneous Psoriasis‐like Skin Inflammation through Enhanced Keratinocyte Response to IL‐17A , 2018, Immunity.

[6]  J. Rebek,et al.  Small Molecule Mimetics of α-Helical Domain of IRAK2 Attenuate the Proinflammatory Effects of IL-33 in Asthma-like Mouse Models , 2018, The Journal of Immunology.

[7]  Weiguo Yin,et al.  Identification of a Constitutively Active Mutant Mouse IRAK2 by Retroviral Expression Screening , 2018, Molecular Biotechnology.

[8]  J. Roh,et al.  Optimization of Cytokine Milieu to Reproduce Atopic Dermatitis-related Gene Expression in HaCaT Keratinocyte Cell Line , 2018, Immune network.

[9]  James T. Elder,et al.  RNA-seq identifies a diminished differentiation gene signature in primary monolayer keratinocytes grown from lesional and uninvolved psoriatic skin , 2017, Scientific Reports.

[10]  F. Ciccarelli,et al.  An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target , 2017, Science Translational Medicine.

[11]  Gao Zhou,et al.  IRAK2 directs stimulus-dependent nuclear export of inflammatory mRNAs , 2017, eLife.

[12]  T. Werfel,et al.  GATA3 regulates FLG and FLG2 expression in human primary keratinocytes , 2017, Scientific Reports.

[13]  J. Gudjonsson,et al.  IL‐1 and IL‐36 are dominant cytokines in generalized pustular psoriasis , 2017, The Journal of allergy and clinical immunology.

[14]  M. Veldhoen.  Interleukin 17 is a chief orchestrator of immunity , 2017, Nature Immunology.

[15]  N. Darwiche,et al.  Retinoids: a journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects , 2017, The Journal of dermatological treatment.

[16]  Hong Wang,et al.  NF-κB-induced microRNA-31 promotes epidermal hyperplasia by repressing protein phosphatase 6 in psoriasis , 2015, Nature Communications.

[17]  Mayte Suárez-Fariñas,et al.  RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications. , 2015, The Journal of allergy and clinical immunology.

[18]  X. Estivill,et al.  Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility , 2015, Nature Communications.

[19]  Bogi Andersen,et al.  A GRHL3-regulated repair pathway suppresses immune-mediated epidermal hyperplasia. , 2014, The Journal of clinical investigation.

[20]  Young Han Park,et al.  The Expression and Role of Krüppel-Like Factor 4 in Psoriasis , 2014, Annals of dermatology.

[21]  E. Davila,et al.  IL-1 Receptor-Associated Kinase Signaling and Its Role in Inflammation, Cancer Progression, and Therapy Resistance , 2014, Front. Immunol..

[22]  James T. Elder,et al.  Cellular dissection of psoriasis for transcriptome analyses and the post-GWAS era , 2014, BMC Medical Genomics.

[23]  P. Elias,et al.  Abnormal Epidermal Barrier Recovery in Uninvolved Skin supports the Notion of an Epidermal Pathogenesis of Psoriasis , 2014, The Journal of investigative dermatology.

[24]  Andrew Johnston,et al.  Transcriptome analysis of psoriasis in a large case-control sample: RNA-seq provides insights into disease mechanisms , 2014, The Journal of investigative dermatology.

[25]  J. Lubiński,et al.  Common variants of ZNF750, RPTOR and TRAF3IP2 genes and psoriasis risk , 2013, Archives of Dermatological Research.

[26]  J. Gudjonsson,et al.  IL-36 Promotes Myeloid Cell Infiltration, Activation, and Inflammatory Activity in Skin , 2013, The Journal of Immunology.

[27]  J. Voorhees,et al.  Robust shifts in S100a9 expression with aging: A novel mechanism for chronic inflammation , 2013, Scientific Reports.

[28]  M. Yi,et al.  IL-1R–MyD88 signaling in keratinocyte transformation and carcinogenesis , 2012, The Journal of experimental medicine.

[29]  Z. Siprashvili,et al.  ZNF750 is a p63 target gene that induces KLF4 to drive terminal epidermal differentiation. , 2012, Developmental cell.

[30]  P. Kwok,et al.  Association analysis identifies ZNF750 regulatory variants in psoriasis , 2011, BMC Medical Genetics.

[31]  J. Krueger,et al.  Contrasting pathogenesis of atopic dermatitis and psoriasis--part II: immune cell subsets and therapeutic concepts. , 2011, The Journal of allergy and clinical immunology.

[32]  J. Krueger,et al.  Contrasting pathogenesis of atopic dermatitis and psoriasis--part I: clinical and pathologic concepts. , 2011, The Journal of allergy and clinical immunology.

[33]  M. Worm,et al.  Decreased retinoid concentration and retinoid signalling pathways in human atopic dermatitis , 2011, Experimental Dermatology.

[34]  A. Bowie,et al.  The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling. , 2010, Biochemical pharmacology.

[35]  H. Ogawa,et al.  Staphylococcus aureus membrane and diacylated lipopeptide induce thymic stromal lymphopoietin in keratinocytes through the Toll-like receptor 2-Toll-like receptor 6 pathway. , 2010, The Journal of allergy and clinical immunology.

[36]  R. Shikiar,et al.  Validity and reliability of patient reported outcomes used in Psoriasis: results from two randomized clinical trials , 2003, Health and Quality of Life Outcomes.

[37]  Y. Lo,et al.  Helical assembly in the MyD88:IRAK4:IRAK2 complex in TLR/IL-1R signaling , 2010, Nature.

[38]  Frank O. Nestle,et al.  Skin immune sentinels in health and disease , 2009, Nature Reviews Immunology.

[39]  A. Poltorak,et al.  A mutation in Irak2c identifies IRAK-2 as a central component of the TLR regulatory network of wild-derived mice , 2009, The Journal of experimental medicine.

[40]  G. Stark,et al.  Interleukin-1 Receptor-associated Kinase 2 Is Critical for Lipopolysaccharide-mediated Post-transcriptional Control* , 2009, Journal of Biological Chemistry.

[41]  Y. Chien,et al.  A promoter sequence variant of ZNF750 is linked with familial psoriasis. , 2008, The Journal of investigative dermatology.

[42]  Osamu Takeuchi,et al.  Sequential control of Toll-like receptor–dependent responses by IRAK1 and IRAK2 , 2008, Nature Immunology.

[43]  Peter M. Elias,et al.  The skin barrier as an innate immune element , 2007, Seminars in Immunopathology.

[44]  W. Hahn,et al.  Human Keratinocytes That Express hTERT and Also Bypass a p16INK4a-Enforced Mechanism That Limits Life Span Become Immortal yet Retain Normal Growth and Differentiation Characteristics , 2000, Molecular and Cellular Biology.

[45]  E. Knol,et al.  Adhesion molecule expression on skin endothelia in atopic dermatitis: Effects of TNF-α and IL-4 , 1998 .

[46]  J. Mansbridge,et al.  Changes in keratinocyte maturation during wound healing. , 1987, The Journal of investigative dermatology.

[47]  D. Orrell,et al.  METHOTREXATE AND RETINOIDS IN COMBINATION FOR PSORIASIS , 1987, The Lancet.

[48]  K. Green,et al.  In Vitro Model of the Epidermis: Connecting Protein Function to 3D Structure. , 2016, Methods in enzymology.

[49]  S. Kojima,et al.  RNA interference in keratinocytes and an organotypic model of human epidermis. , 2010, Methods in molecular biology.